Medigen, Inc.

FREDERICK, MD 21701

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $3.06MM
First Award Date 01/01/11
Most Recent Award Date 02/01/17

Key Personnel

Last Name Name Awards Contact
Pushko Peter M Pushko 9 Message

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/17 - 01/31/18

? DESCRIPTION (provided by applicant): Venezuelan Equine Encephalitis virus (VEEV) is a life-threatening, NIH/NIAID category B human pathogen and a potential bioterrorism threat. Outbreaks of VEEV occur in Central America and have previously spread into the United States. The potentially devastating effects of the virus reemergence in the U....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): Venezuelan Equine Encephalitis virus (VEEV) is a life-threatening, NIH/NIAID category B human pathogen and a potential bioterrorism threat. Outbreaks of VEEV occur in Central America and have previously spread into the United States. The potentially devastating effects of the virus reemergence in the U....

Phase 2 SBIR

Agency: Department of Agriculture
Topic: 8.3-2013
Budget: 01/01/13 - 12/31/13

Medigen successfully designed and tested a conceptually novel VLP design as a vaccine for avian influenza (AI). This vaccine isnot dependent on egg production and allows protection against multiple AI viruses by using a single preparation of VLP vaccine. For example, we demonstrated that co-expression of H5, H7, and H9 HA proteins along with oth...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/12 - 05/31/13

DESCRIPTION (provided by applicant): Venezuelan Equine Encephalitis virus (VEEV) is a dangerous, NIH/NIAID category B human pathogen and a potential bioterrorism threat. Outbreaks of VEEV occur in Central America and have previously spread into the United States. The potentially devastating effects of the virus reemergence in the U.S. demand an ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/15/11 - 06/30/13

DESCRIPTION (provided by applicant): Arenaviruses represent a rapidly growing group of emerging rodent-borne viruses. Highly pathogenic arenaviruses, Lassa (LASV), Junun (JUNV), and Machupo (MACV), are the most prevalent arenaviruses in the world that represent the emerging severe threat to the U.S. public health. The development of safe and eff...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/11 - 05/31/12

DESCRIPTION (provided by applicant): Venezuelan Equine Encephalitis virus (VEEV) is a dangerous, NIH/NIAID category B human pathogen and a potential bioterrorism threat. Outbreaks of VEEV occur in Central America and have previously spread into the United States. The potentially devastating effects of the virus reemergence in the U.S. demand an ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 01/15/11 - 10/31/12

DESCRIPTION (provided by applicant): Live attenuated vaccine 17D has been used since the 1950s for vaccination against yellow fever (YF) with a remarkable record of safety and efficacy. More than 500 million people have been vaccinated, and the World Health Organization (WHO) strongly recommends to continue vaccinations in at-risk countries. The...

Phase 1 SBIR

Agency: Department of Agriculture
Topic: 8.3-2011
Budget: 01/01/11 - 12/31/11

In this Phase I SBIR application, we propose the trivalent influenza virus-like particle (VLP) vaccine that is not dependent on egg production and allows protection of poultry against multiple AI viruses. Our hypothesis is that expression of H5, H7, and H9 HA proteins will result in a trivalent vaccine that will contain HA proteins derived from ...